Cardioprotective effects of compound ALM-802 on subendocardial ischemia models
I. B. Tsorin,
V. V. Barchukov,
M. B. Vititnova,
A. M. Likhosherstov,
G. V. Mokrov,
S. A. Kryzhanovskii https://doi.org/10.37489/2587-7836-2021-1-18-22
Abstract
The investigation purpose. N1-(2,3,4-trimethoxybenzyl)-N2-{2-[(2,3,4-trimethoxybenzyl)amino]ethyl}-1,2-ethanediamine (ALM-802 compounds) cardioprotective effect has been studied in rat models of subendocardial ischemia caused by isoproterenol and dobutamine. Material and methods. Acute subendocardial myocardial ischemia in anesthetized rats (urethane 1300 mg/kg, i.p.) was caused by infusion of isoproterenol (20 µg/kg/min i.v.) or dobutamine (80 µg/kg/min i.v.). Results. It was shown that in anesthetized rats, isoproterenol and dobutamine caused almost the same ST-segment depression in the II standard ECG lead. The compound ALM-802 (2 mg/kg i.v.), administered 2 minutes before the infusion start of isoproterenol or dobutamine, equally prevented the occurrence of ischemic changes on the ECG. Conclusion. The non-selective beta-adrenomimetic isoproterenol and the selective β1-adrenomimetic dobutamine cause subendocardial ischemia of the same intensity in anesthetized rats. The compound ALM-802 has a pronounced anti-ischemic effect on both models.
About the Authors
I. B. Tsorin
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Tsorin Iosif B., Dr. Sci. Biological, Leading researcher of laboratory of pharmacological screening
SPIN code: 4015-3025
Moscow
V. V. Barchukov
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Barchukov Vladimir V., Research scientist of laboratory of pharmacological screening
SPIN code: 6743-4280
Moscow
M. B. Vititnova
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Vititnova Marina B., PhD Biological Sci., Senior researcher scientist of laboratory of pharmacological screening
SPIN code: 1901-8919
Moscow
A. M. Likhosherstov
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Likhosherstov Arkady M., PhD Chemical Sci., Consultant of drug chemistry department
SPIN code: 1980-7331
Moscow
G. V. Mokrov
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Mokrov Grigory V., PhD Chemical Sci., Leading researcher of the fine organic synthesis laboratory at the drug chemistry department
SPIN code: 8755-7666
Moscow
S. A. Kryzhanovskii
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Kryzhanovskiy Sergey A., Dr. Sci. (Med.), Head of laboratory of pharmacological screening
SPIN code: 6596-4865
Moscow
References
1. Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002;27(7):621–636. DOI: 10.1007/s00059-002-2428-x.
2. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation – a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta. 2011;1813(7):1333–1350. DOI: 10.1016/j.bbamcr.2011.01.015.
3. Fukushima A, Milner K, Gupta A, Lopaschuk GD. Myocardial energy substrate metabolism in heart failure: From pathways to therapeutic targets. Curr Pharm Des. 2015;21(25):3654–3664. DOI: 10.2174/13816128216661 50710150445.
4. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res. 2004;61(2):218–226. DOI: 10.1016/j.cardiores.2003.11.014.
5. Mamamtavrishvili N, Sanikidze T, Pavliashvili N, Kvirkvelia A, Narsia E. Some aspects of metabolic remodeling of myocard during chronic heart failure. Georgian Med. News. 2008;(154):33–36.
6. Tuunanen H, Knuuti J. Metabolic remodelling in human heart failure. Cardiovasc Res. 2011;90(2):251–257. DOI: 10.1093/cvr/cvr052.
7. Lam A, Lopaschuk GD. Anti-anginal effects of partial fatty acid oxidation inhibitors. Curr Opin Pharmacol. 2007;7(2):179–185. DOI: 10.1016/j.coph.2006.10.008.
8. Bhandari B, Subramanian L. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorder. Recent Pat Cardiovasc Drug Discov. 2007;2(1):35–39. DOI: 10.2174/157489007779606095.
9. Крыжановский С.А., Лихошерстов А.М., Цорин И.Б., Столярук В.Н., Вититнова М.Б., Мокров Г.В., Гудашева Т.А. Скрининг кардиотропной активности в ряду α, ω-диарилметильных производных бис-(ω- аминоалкил)аминов. Фармакокинетика и Фармакодинамика. 2016;(2):10– 13. [Kryzhanovskii SA, Likhosherstov AM, Tsorin IB, Stolyaruk VN, Vititnova MB, Mokrov GV, Gudasheva TA. Screening of the compounds having cardiotropic activity among the α, ω-diarilmetil derivatives of bis-(ω-aminoalkyl) amines. Farmakokinetika i Farmakodinamika. 2016;(2):10–13. (In Russ).].
10. Yamamoto S, Matsui K, Sasabe M, Ohashi NJ. Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats. J Cardiovasc Pharmacol. 2002;39(2): 234–241. DOI: 10.1097/00005344-200202000-00010.
11. Барчуков В.В., Цорин И.Б., Лихошерстов А.М., Вититнова М.Б., Мокров Г.В., Гудашева Т.А., Крыжановский С.А. Противоишемическая активность триамина АЛМ-802 в условиях эндотелиальной дисфункции. Бюллетень экспериментальной биологии и медицины. 2019;167(4):443– 446. [Barchukov VV, Tsorin IB, Likhosherstov AM, Vititnova MB, Mokrov GV, Gudasheva TA, Kryzhanovskii SA. Anti-ischemic activity of triamine ALM-802 under conditions of endothelial dysfunction. Bulletin of Experimental Biology and Medicine. 2019;167(4):443–446.
12. Барчуков В.В., Цорин И.Б., Лихошерстов А.М., Вититнова М.Б., Мокров Г.В., Крыжановский С.А. Cравнительное изучение антиишемической активности триметазидина и соединения АЛМ-802 в условиях эндотелиальной дисфункции. Фармакокинетика и фармакодинамика. 2019;(2):23–27. [Barchukov VV, Tsorin IB, Likhosherstov AM, Vititnova MB, Mokrov GV, Kryzhanovskii SA. A comparative study of the anti-ischemic activity of trimetazidine and the compound ALM-802 under conditions of endothelial dysfunction. Farmakokinetika i Farmakodinamika. 2019;(2):23– 27. (In Russ).]. DOI: 10.24411/2587-7836-2019-10042.
Review
For citations:
Tsorin I.B., Barchukov V.V., Vititnova M.B., Likhosherstov A.M., Mokrov G.V., Kryzhanovskii S.A. Cardioprotective effects of compound ALM-802 on subendocardial ischemia models. Pharmacokinetics and Pharmacodynamics. 2021;(1):18-22. (In Russ.) https://doi.org/10.37489/2587-7836-2021-1-18-22
Views:
648
Email this article 